skip to Main Content

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.

© 2025 AccentBio. All Rights Reserved.
Site designed by Grid24 a division of Grid24 Ltd.

Back To Top